先声药业(02096.HK) 公布,与嘉兴安帝康生物科技合作的抗流感药物玛氘诺沙韦片新药上市申请,于上周六(15日)获国家药品监督管理局受理,用于治疗成人及青少年无并发症的甲型和乙型流感。
公告引述研究结果指,玛氘诺沙韦具有无中枢神经系统副作用、口服吸收不受食物影响、更高安全剂量等优势。玛氘诺沙韦片全程口服剂量仅为“一粒”,并可在24小时内阻断流行性感冒病毒复制。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-14 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.